{"id":"nct:NCT05809908","kind":"trial","title":"Tricaprilin Phase 3 ALTER-AD (Alternative-Alzheimer Disease) Study","authors":["Cerecin"],"author_count":1,"year":2023,"published":"2023-04-12","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT05809908","source_url":"https://clinicaltrials.gov/study/NCT05809908","archive_url":"https://space-kitty.com/papers/nct:NCT05809908","updated":"2026-07-01","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"The purpose of this study is to evaluate the effects of tricaprilin (20 g twice a day) on cognition, global function, activities of daily living, resource utilisation, safety, and tolerability, in participants with mild to moderate AD dementia. This is a randomised, double-blind, placebo-controlled, parallel-group, multi-centre design in up to 535 participants.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Alzheimer Disease"],"details":{"acronym":"ALTER-AD","status":"NOT_YET_RECRUITING","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":535,"sponsor":"Cerecin","conditions":["Alzheimer Disease"],"interventions":["DRUG: Tricaprilin","DRUG: Placebo"],"start_date":"2026-12-01","start_date_type":"ESTIMATED","primary_completion_date":"2029-06-01","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"neurodegeneration","name":"Alzheimer's, Parkinson's & Neurodegeneration","domain_slug":"medicine"}],"cited_in_dossiers":[]}